- Early research suggests a new slow-release ketamine pill could offer a promising option for treating hard-to-treat depression with fewer side effects compared to existing treatments. While no form of ketamine has FDA approval for psychiatric disorders, derivatives like esketamine are used off-label and require clinic-based administration due to potential side effects. The new pill aims to simplify treatment by allowing patients to manage it at home, potentially widening access to effective depression care. In a recent study published in Nature Medicine, participants taking the pill showed significant symptom improvement, with higher doses correlating with better outcomes, indicating potential efficacy though further research is needed to confirm these findings in broader populations. (Article here)
July 16, 2024
Life Sciences | Tea Leaves